A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CFTX-1554 in Healthy Subjects, With Comparison of Intake of CFTX-1554 as Liquid Formulation and as Capsule, and After a High-fat Breakfast Versus Fasted
Latest Information Update: 07 Sep 2023
At a glance
- Drugs CFTX-1554 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors Confo Therapeutics
- 01 Sep 2023 Status changed from recruiting to completed.
- 10 Mar 2022 According to a Confo Therapeutics media release, first subjects have been dosed in this study.
- 18 Feb 2022 Status changed from planning to recruiting.